Ampersand Biomedicines
Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.
AbCheck
Acquisition in 2024
AbCheck specializes in the discovery and optimization of human therapeutic antibodies through a versatile antibody discovery platform. Founded in 2009 as a spin-out of Affimed's technology discovery platform, the company collaborates with partners to provide drug candidates under flexible terms, including royalty-free agreements. AbCheck generates target-specific human antibody domains that can be utilized in various therapeutic formats. By employing both de novo antibody discovery from animals and libraries of human antibodies, including humanized libraries cloned from immunized rabbits, the company enables clients to identify unique antibody sequences tailored for cancer immunotherapy. As a wholly owned subsidiary of Affimed GmbH, AbCheck contributes to the advancement of highly targeted cancer treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.